GoAI
Get started
Pulmonx Corporation logo

Pulmonx Corporation

LUNG

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$2.26

−$0.04 · -1.74%

Aug 21, 4:00 PM ET

LUNG company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

69

Undervalued

Momentum

40

Weakening

Sentiment

39

Bearish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Glendon E. French
Listed since
Oct 1, 2020
Employees
296

Market position

Day range

Current $2.26

52-week range

Current $2.26

Open
$2.31
Previous close
$2.30
Volume
610.2K
1.09× average
Average volume
559.63K
Average daily volume
Market cap
95.46M USD
Beta
0.28
Market reference 1
50-day average
$1.6137
+40.05% above average
200-day average
$1.6475
+37.18% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
76.27M USD
P/E (TTM)
-1.97×
P/B (TTM)
2.43×
P/S (TTM)
1.09×
EV / EBITDA
-1.55×
Earnings yield
-60.06%
Free cash flow yield
-36.59%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
77.06%
Operating margin
-52.96%
Net margin
-55.03%
Return on equity
-99.79%
Return on assets
-41.77%
Return on invested capital
-48.54%

Financial health

Debt / equity
1.43×
Current ratio
5.07×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends93%19%-55%-128%Gross margin, FY2021: 73.59%Gross margin, FY2022: 74.29%Gross margin, FY2023: 73.90%Gross margin, FY2024: 74.00%Gross margin, FY2025: 74.19%Operating margin, FY2021: -97.70%Operating margin, FY2022: -109.27%Operating margin, FY2023: -90.19%Operating margin, FY2024: -68.87%Operating margin, FY2025: -59.30%Net margin, FY2021: -100.51%Net margin, FY2022: -109.80%Net margin, FY2023: -88.60%Net margin, FY2024: -67.30%Net margin, FY2025: -59.67%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 73.59%. Gross margin FY2022 74.29%. Gross margin FY2023 73.90%. Gross margin FY2024 74.00%. Gross margin FY2025 74.19%. Operating margin FY2021 -97.70%. Operating margin FY2022 -109.27%. Operating margin FY2023 -90.19%. Operating margin FY2024 -68.87%. Operating margin FY2025 -59.30%. Net margin FY2021 -100.51%. Net margin FY2022 -109.80%. Net margin FY2023 -88.60%. Net margin FY2024 -67.30%. Net margin FY2025 -59.67%.

Income trends

Revenue

90.5M USD+8.01%

Operating income

−53.66M USD+7.00%

Net income

−54M USD+4.24%
Income trends across reported periods105.74M USD44.77M USD−16.21M USD−77.18M USDRevenue, FY2021: 48.42M USDRevenue, FY2022: 53.66M USDRevenue, FY2023: 68.68M USDRevenue, FY2024: 83.79M USDRevenue, FY2025: 90.5M USDOperating income, FY2021: −47.3M USDOperating income, FY2022: −58.64M USDOperating income, FY2023: −61.94M USDOperating income, FY2024: −57.7M USDOperating income, FY2025: −53.66M USDNet income, FY2021: −48.66M USDNet income, FY2022: −58.92M USDNet income, FY2023: −60.84M USDNet income, FY2024: −56.39M USDNet income, FY2025: −54M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 48.42M USD. Revenue FY2022 53.66M USD. Revenue FY2023 68.68M USD. Revenue FY2024 83.79M USD. Revenue FY2025 90.5M USD. Operating income FY2021 −47.3M USD. Operating income FY2022 −58.64M USD. Operating income FY2023 −61.94M USD. Operating income FY2024 −57.7M USD. Operating income FY2025 −53.66M USD. Net income FY2021 −48.66M USD. Net income FY2022 −58.92M USD. Net income FY2023 −60.84M USD. Net income FY2024 −56.39M USD. Net income FY2025 −54M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue90.5M USD83.79M USD68.68M USD53.66M USD48.42M USD
Cost of goods sold23.36M USD21.79M USD17.92M USD13.8M USD12.79M USD
Gross profit67.14M USD62M USD50.75M USD39.87M USD35.63M USD
Research and development19.49M USD17.57M USD18.08M USD15.4M USD13.06M USD
Selling, general, and administrative101.31M USD102.14M USD94.61M USD83.11M USD69.87M USD
Operating expenses120.8M USD119.71M USD112.69M USD98.5M USD82.93M USD
Interest income2.65M USD5.06M USD5.57M USD1.53M USD400K USD
Interest expense3.16M USD3.51M USD3.23M USD1.07M USD829K USD
Depreciation and amortization1.05M USD1.59M USD1.95M USD1.51M USD867K USD
Operating income−53.66M USD−57.7M USD−61.94M USD−58.64M USD−47.3M USD
Net income−54M USD−56.39M USD−60.84M USD−58.92M USD−48.66M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
91%
10 beats, 0 misses, 1 met estimate
Average EPS surprise
+13.15%
11 comparable reports
Latest EPS result
-0.24
Estimate -0.28 · Beat by 14.29%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.2-0.3-0.39-0.49Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 19, 2025: actual -0.33, estimate -0.45, surprise +26.67%, Beat. Q2 2025, reported Apr 30, 2025: actual -0.36, estimate -0.37, surprise +2.70%, Beat. Q3 2025, reported Jul 30, 2025: actual -0.38, estimate -0.4, surprise +5.00%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.34, estimate -0.4, surprise +15.00%, Beat. Q1 2026, reported Mar 4, 2026: actual -0.25, estimate -0.39, surprise +35.90%, Beat. Q2 2026, reported Apr 29, 2026: actual -0.33, estimate -0.33, surprise 0.00%, Met estimate. Q3 2026, reported Jul 29, 2026: actual -0.24, estimate -0.28, surprise +14.29%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.26, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates24.81M23.03M21.26M19.48MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 19, 2025: actual 23.77M USD, estimate 22.29M USD, surprise +6.61%, Beat. Q2 2025, reported Apr 30, 2025: actual 22.54M USD, estimate 22.03M USD, surprise +2.29%, Beat. Q3 2025, reported Jul 30, 2025: actual 23.86M USD, estimate 23.39M USD, surprise +1.99%, Beat. Q4 2025, reported Nov 12, 2025: actual 21.5M USD, estimate 21.73M USD, surprise -1.04%, Miss. Q1 2026, reported Mar 4, 2026: actual 22.6M USD, estimate 21.73M USD, surprise +4.00%, Beat. Q2 2026, reported Apr 29, 2026: actual 20.59M USD, estimate 20.43M USD, surprise +0.76%, Beat. Q3 2026, reported Jul 29, 2026: actual 22.76M USD, estimate 22.39M USD, surprise +1.62%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate 21.93M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$10.00

342.48% upside
Past 12 months12-month forecastHigh $20.00Average $10.00Low $2.50

Rating distribution

9 ratings
Strong buy00%
Buy444%
Hold444%
Sell111%
Strong sell00%

LUNG peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding LUNG

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.88M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
752.42K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
319.58K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research LUNG

research.disclaimer